Merck's Lipfendra beats AstraZeneca's laroprovstat to become the first oral PCSK9 pill, priced at $10.50/day with $370M in 2027 sales forecast.
As in football, so in pharmaceuticals: the English have been beaten.
Merck has outpaced AstraZeneca in the race to get the first US approval for …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Merck wins first approval of a PCSK9 cholesterol pill
Merck gets US FDA nod for first-in-its-class oral cholesterol drug
FDA approves new kind of cholesterol pill
FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)
Merck’s cholesterol pill gets US FDA approval | CNN
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
The cholesterol shot you couldn’t afford is now a pill | Fortune
FDA Approves First PCSK9 Inhibitor in Pill Form
FDA approves first pill to significantly lower 'bad' cholesterol - UPI.com
FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
